Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

AMRAMR Advanced Multidisciplinary Research for Antimicrobial Resistance

Coordinator
Alma Mater Studiorum - Universita Di Bologna, Italy
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€276k
Total cost
—
Partners
8 organisations in 6 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101131231

What the project is doing

In the project's own words, from its summary on CORDIS.

We are proposing a 4-year program of knowledge transfer and networking between academic institutions [University of Leicester (UK), University of Valencia (Spain), International Iberian Nanotechnology Lab (Portugal), University of Bologna (Italy), University of Aveiro (Portugal), Fudan University (China), and Alfred University (USA)] and industrial partners [Teer Coatings Ltd (UK)]. The objective of the proposed joint exchange programme is to establish long-term stable research cooperation between the partners with interdisciplinary expertise and knowledge to develop Advanced Multidisciplinary Research for Antimicrobial Resistance (AMRAMR), including the development of novel antibacterial nanomaterials and nanostructures, novel antibacterial thin films coatings, upconversion technology for AMR applications, photonics technology for AMR application, and evaluation of the antibacterial performance and antimicrobial resistance; the synergetic effect for the above approaches to understanding antimicrobial resistance.

Antimicrobial resistance (AMR) refers to the ability of microorganisms, such as bacteria, viruses, fungi, and parasites, to resist the effects of antimicrobial drugs, such as antibiotics, antivirals, antifungals, and antiparasitics. AMR is a serious global public health threat that could lead to increased morbidity, mortality, and healthcare costs. World Health Organisation (WHO) has declared that AMR is one of the top 10 global public health threats facing humanity.

The COVID-19 pandemic has highlighted the importance of AMR as it has led to increased use of antimicrobial drugs, particularly antibiotics, which can contribute to the development of AMR. People with COVID-19 may develop secondary bacterial infections, such as pneumonia, and may be prescribed antibiotics to treat these infections. However, unnecessary use of antibiotics can lead to the emergence and spread of resistant bacteria, making it more difficult to treat infections in the future.

Topics

Who is involved

OrganisationCityCountryRole
Alma Mater Studiorum - Universita Di BolognaBolognaItalyCoordinator
Fudan UniversityShanghaiChinaAssociatedpartner
Universitat De ValenciaValenciaSpainParticipant
International Iberian Nanotechnology LaboratoryBragaPortugalParticipant
Universidade De AveiroAveiroPortugalParticipant
Teer Coatings LimitedDroitwichUnited KingdomAssociatedpartner
University of LeicesterLeicesterUnited KingdomAssociatedpartner
Alfred University Foundation IncAlfredUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI